Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing.

• Main Authors: Stefanie K Menzies (Author), Thea Litschka-Koen (Author), Rebecca J Edge (Author), Jaffer Alsolaiss (Author), Edouard Crittenden (Author), Steven R Hall (Author), Adam Westhorpe (Author), Brent Thomas (Author), James Murray (Author), Nondusimo Shongwe (Author), Sara Padidar (Author), David G Lalloo (Author), Nicholas R Casewell (Author), Jonathan Pons (Author), Robert A Harrison (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<h4>Background</h4>Snakebite is a major public health concern in Eswatini, where treatment relies upon one antivenom-SAIMR Polyvalent. Although effective in treating snakebite, SAIMR Polyvalent is difficult to source outside its manufacturing country (South Africa) and is dauntingly expe...